- Pfizer forms licensing agreement with Seattle Genetics
- 3Rx Skin Therapy's new line targets skin damaged by medical conditions
- Senator to float bill to address drug shortages
- Medco study: Half of women 40 years and older don’t get annual mammograms
- Adherence among chronic disease patients can lead to big savings
PITTSBURGH — Mylan has released a generic version of a drug used to treat a complication of certain chemotherapy regimens, the drug maker said Tuesday.
The company announced the launch of mesna injection in the 100-mg/mL and 1,000-mg/10-mL strengths. The drug is used to reduce the incidence of ifosfamide-induced hemorrhagic cystitis, a possible complication of ifosfamide chemotherapy.
The drug is a generic version of Baxter Healthcare's Mesnex, which has experienced shortages recently. Various versions of the drug had sales of about $11.7 million in 2011, according to IMS Health.